Israeli-British investment house: Two large companies consider dual-listing in UK

Two large companies that are traded on the Tel Aviv Stock Exchange are considering listing in the UK, Israeli-British investment house MG Equity Partners said Tuesday.

January 11, 2006 08:47
3 minute read. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Two large companies that are traded on the Tel Aviv Stock Exchange are considering listing in the UK, Israeli-British investment house MG Equity Partners said Tuesday. Robert Pincas, a partner at the firm, declined to identify the companies, saying it was too early to disclose the information. However, he forecast that a total of 20 companies would list on the London Stock Exchange this year, with five to eight being those that already listed on the TASE. Last year, 19 Israeli companies registered in London and only Australia provided more listings. More than 30 Israeli companies are listed in the UK, including Partner Communications, Bank Hapoalim, Frutarom and XTL Biopharmaceuticals, all of which also hold a TASE listing. The latter two became dual-listed last year. Until now, many Israeli companies that have registered in London have been hi-tech start-ups that listed on the LSE's Alternative Investment Market, which is designed for smaller, high-growth companies. However, Pincas believes the time is ripe for larger firms to list in the UK. "In the last year and a half, there has been a dating process between Israeli companies and the LSE and we expect a larger number of the bigger companies to list," he said. "I think most of those them will be from the Tel Aviv-25." "The real estate sector draws a lot of interest, and Strauss-Elite has already said it is looking at the LSE," Pincas noted, adding that retail and energy companies would also be suitable for dual-listings. In partnership with UK investment house KBC Peel Hunt, which led the $53 million IPO of real estate company Engel East Europe last month, MG Equity is organizing a conference at the start of February to promote the benefits of dual-listing. "It provides the ability to raise significant amounts of money at a higher [company] value than on the Israeli exchange," said Pincas, adding that in the UK there are also a wider variety of international investors and greater trading in dual-listed stocks because of arbitrage, which is the difference in the price of a share that is traded on two exchanges. "Arbitrage creates liquidity because it creates an incentive for investors to trade on the variation in the prices on the different exchanges," he said. Dual-listing also shields companies from total exposure to political and economic instability in Israel, such as with the illness of Prime Minister Ariel Sharon. "Institutional investors in London care less about what is going on here than those in Israel. By dual-listing you reduce the political risk of being in Israel, although everything still depends on how a company performs," Pincas said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection